Data gathered: May 6
AI Stock Analysis - Johnson & Johnson (JNJ)
Analysis generated March 10, 2025. Powered by Chat GPT.
Johnson & Johnson, founded in 1886, is a global leader in the pharmaceuticals, medical devices, and consumer health products sectors. With a broad range of products, from consumer health items like baby products and Band-Aids to complex pharmaceuticals and medical devices, the company has a well-diversified revenue base. Its substantial market presence and brand value contribute to its status as a blue-chip stock.
Stock Alerts - Johnson & Johnson (JNJ)
 |
Johnson & Johnson | May 5 Job postings are down by 23.3% in the last couple of days. |
|
Johnson & Johnson | May 1 Job postings are down by 26.9% in the last couple of days. |
|
Johnson & Johnson | April 29 Rob Bresnahan (member of U.S. congress) is selling shares |
|
Johnson & Johnson | April 28 Job postings are down by 27.3% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
| Price | $155.00 |
| Target Price | Sign up |
| Volume | 5,460,000 |
| Market Cap | $376B |
| Year Range | $140.93 - $167.7 |
| Dividend Yield | 3.33% |
| PE Ratio | 17.37 |
| Analyst Rating | 43% buy |
| Industry | Drug Manufacturers |
In the news
Was Jim Cramer Right About Johnson & Johnson (JNJ)?May 5 - Yahoo Entertainment |
|
If You Invested $10K In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?May 4 - Yahoo Entertainment |
|
 |
Is Johnson & Johnson (JNJ) The Most Profitable Cheap Stock to Buy Now?May 4 - Yahoo Entertainment |
 |
Zacks Research Has Bullish Forecast for JNJ FY2025 EarningsMay 2 - ETF Daily News |
JNJ-Backed Histosonics Is Pursuing A Sale After Fielding Takeover Bids, Seeking A Valuation Of More Than $2.5 Billion - FTMay 1 - Finnhub |
|
Schizophrenia Drugs Market Size and Shares Analysis (2025-2033) Featuring H Lundbeck, Pfizer, AbbVie, AstraZeneca, BMS, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, Takeda PharmaceuticalsMay 1 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 21.9B | 7.36B | 14.5B | 11B | 0 | 2.770 |
| Q4 '24 | 22.5B | 7.13B | 15.4B | 3.43B | 5.92B | 2.040 |
| Q3 '24 | 22.5B | 6.96B | 15.5B | 2.69B | 5.38B | 2.420 |
| Q2 '24 | 22.4B | 6.87B | 15.6B | 4.69B | 7.8B | 2.820 |
| Q1 '24 | 21.4B | 6.51B | 14.9B | 3.26B | 5.68B | 2.710 |
Insider Transactions View All
| Decker Robert J filed to sell 21,001 shares at $165.9. February 26 '25 |
| Schmid Timothy filed to sell 15,098 shares at $156.2. February 18 '25 |
| WEINBERGER MARK A filed to buy 1,000 shares at $147.2. December 12 '24 |
| Decker Robert J filed to sell 18,973 shares at $165.1. September 3 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Eli Lilly and CompanyLLY |
$821.46 0% | 65 |
 |
PfizerPFE |
$23.87 0% | 38 |
 |
AstrazenecaAZN |
$72.09 0% | 44 |
 |
AbbVieABBV |
$196.07 0% | 46 |
 |
TherapeuticsMDTXMD |
$1.43 0% | 43 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Apr 29, 25 | Sell | $1K - $15K |
| George Whitesides |
Apr 24, 25 | Sell | $100K - $250K |
| Bruce Westerman |
Apr 17, 25 | Buy | $1K - $15K |
Read more about Johnson & Johnson (JNJ) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Johnson & Johnson?
The Market Cap of Johnson & Johnson is $376B.
What is Johnson & Johnson's PE Ratio?
As of today, Johnson & Johnson's PE (Price to Earnings) ratio is 17.37.
What is the current stock price of Johnson & Johnson?
Currently, the price of one share of Johnson & Johnson stock is $155.00.
How can I analyze the JNJ stock price chart for investment decisions?
The JNJ stock price chart above provides a comprehensive visual representation of Johnson & Johnson's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Johnson & Johnson shares. Our platform offers an up-to-date JNJ stock price chart, along with technical data analysis and alternative data insights.
Does JNJ offer dividends to its shareholders?
Yes, Johnson & Johnson (JNJ) offers dividends to its shareholders, with a dividend yield of 3.33%. This dividend yield represents Johnson & Johnson's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Johnson & Johnson in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Johnson & Johnson?
Some of the similar stocks of Johnson & Johnson are Eli Lilly and Company, Pfizer, Astrazeneca, AbbVie, and TherapeuticsMD.
.